Facilitated By

San Antonio Medical Foundation

A Randomized, Open-Label, Phase 3 Trial of EPCORITAMAB vs. Investigator?s Choice Chemotherapy In Relapsed/Refractory Diffuse Large B-CELL Lymphoma

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
HJF
Research Start Date
Status
Active

The primary objective of the study is to compare the clinical efficacy, safety and tolerability of epcoritamab to investigator's choice of standard of care (SOC) R-GemOx or BR for large B-cell lymphoma.

Collaborative Project
Clinical Care
Cancer
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.